CareDx (CDNA) Stock Overview
Provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for CDNA from our risk checks.
CDNA Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
CareDx, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.74 |
| 52 Week High | US$21.49 |
| 52 Week Low | US$10.96 |
| Beta | 2.59 |
| 1 Month Change | -8.89% |
| 3 Month Change | -7.84% |
| 1 Year Change | -1.93% |
| 3 Year Change | 81.21% |
| 5 Year Change | -75.90% |
| Change since IPO | 77.40% |
Recent News & Updates
Recent updates
CareDX Has Reached An Inflection Point, But Regulatory Risks Remain (Upgrade)
Dec 22CareDx, Inc's (NASDAQ:CDNA) Shares Bounce 25% But Its Business Still Trails The Industry
Nov 29
We Believe CareDx's (NASDAQ:CDNA) Earnings Are A Poor Guide For Its Profitability
Nov 12CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Sep 19Calculating The Intrinsic Value Of CareDx, Inc (NASDAQ:CDNA)
Aug 27The Market Doesn't Like What It Sees From CareDx, Inc's (NASDAQ:CDNA) Revenues Yet As Shares Tumble 32%
Jul 23Is There An Opportunity With CareDx, Inc's (NASDAQ:CDNA) 28% Undervaluation?
May 02
AlloMap Testing And OPTN Project Will Expand Markets Despite Risks
CareDx's growth fueled by expanded testing services and strategic investments aims to improve margins and revenue cycle management.CareDx: Some Litigation Clouds Have Cleared
Mar 13Why CareDx's (NASDAQ:CDNA) Earnings Are Weaker Than They Seem
Mar 11CareDx: Too Risky For Me
Dec 30The Market Doesn't Like What It Sees From CareDx, Inc's (NASDAQ:CDNA) Revenues Yet As Shares Tumble 26%
Nov 05CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics
Sep 29CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 34% But Its Business Prospects Need A Lift Too
Aug 01CareDx: Benefiting From Some Certainty
Jul 15Why Investors Shouldn't Be Surprised By CareDx, Inc's (NASDAQ:CDNA) 28% Share Price Plunge
Apr 27CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 40% But Its Business Prospects Need A Lift Too
Mar 02CareDx, Inc's (NASDAQ:CDNA) Shares Bounce 26% But Its Business Still Trails The Industry
Dec 27CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 27Shareholder Returns
| CDNA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.4% | -1.2% | -1.5% |
| 1Y | -1.9% | 25.9% | 21.3% |
Return vs Industry: CDNA underperformed the US Biotechs industry which returned 22.8% over the past year.
Return vs Market: CDNA underperformed the US Market which returned 16.9% over the past year.
Price Volatility
| CDNA volatility | |
|---|---|
| CDNA Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CDNA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CDNA's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 763 | John Hanna | caredx.com |
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes.
CareDx, Inc. Fundamentals Summary
| CDNA fundamental statistics | |
|---|---|
| Market cap | US$916.26m |
| Earnings (TTM) | -US$21.35m |
| Revenue (TTM) | US$379.81m |
Is CDNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDNA income statement (TTM) | |
|---|---|
| Revenue | US$379.81m |
| Cost of Revenue | US$123.24m |
| Gross Profit | US$256.57m |
| Other Expenses | US$277.92m |
| Earnings | -US$21.35m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 67.55% |
| Net Profit Margin | -5.62% |
| Debt/Equity Ratio | 0% |
How did CDNA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/09 07:01 |
| End of Day Share Price | 2026/03/09 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CareDx, Inc. is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Mark Massaro | BTIG |
| William Bonello | Craig-Hallum Capital Group LLC |